With the demonstration of classical nuclear progesterone receptor (nPRs) in some cancers, e.g., breast, ovarian, and endometrial cancers, the hope was that the nPR was essential for cancer growth, so that by blocking the nPR cancer, progression could be halted. The gene discussed is NPTXR; the disease is endometrial cancer.